A major recall of thyroid medicine has been issued in Australia, with the Therapeutic Goods Administration (TGA) advising patients to stop taking two specific formulations due to contamination concerns. The affected medications, Levothyroxine 100mcg and Levothyroxine 200mcg, have been distributed by local pharmaceutical company, Melbourne Pharmaceuticals, to pharmacies and hospitals nationwide.
According to sources, the recall was triggered after a batch of the medicines was found to contain high levels of particulate matter, which could potentially cause health issues in patients with pre-existing thyroid conditions. While no adverse reactions have been reported so far, the TGA has issued a nationwide alert to ensure the safety of consumers. Patients who have been prescribed the recalled medicines are advised to contact their healthcare providers for alternative treatment options.
Melbourne Pharmaceuticals has since issued a statement apologizing for the inconvenience caused and assuring consumers that they are working closely with the TGA to identify the root cause of the contamination and implement corrective measures to prevent similar incidents in the future.